NDAINJECTIONSOLUTION
Approved
Sep 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIVFLOZA (nedosiran) is an oligonucleotide therapeutic administered by injection in solution form. It is developed by Novo Nordisk and represents an RNA-based modality targeting hepatic oxalate production. The exact indication and mechanism of action require clinical context, but the oligonucleotide class typically addresses metabolic disorders through RNA interference or antisense mechanisms.
Peak11.9 years to LOE
Early peak-phase product with limited competitive pressure suggests focused teams building market access and specialty pharmacy infrastructure for rare disease positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Started Feb 2022
27 enrolled
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2+1 more
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Primary Hyperoxaluria Type 1 (PH1)
Career Relevance
RIVFLOZA careers center on rare disease commercialization, specialty pharmacy partnerships, and payer negotiation in an uncontested market. This is an opportunity to build category presence and shape treatment paradigms with limited defensive competitive pressure.
Brand Manager
Worked on RIVFLOZA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.